China Natural Kidney Medicine,Vitamin C Minoxidil manufacturer, choose the high quality Dinoprostone Api Powder,Yohimbine Hcl Powder, etc. Natural Kidney Medicine,Vitamin C Minoxidil,Dinoprostone Api Powder,Yohimbine Hcl Powder Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikang.com
It has absolute advantage because of strong research strength, modern management system and high-quality marketing team.
Now we have 3 GMP standard workshop, Meanwhile, the factory is equipped with the researching and quality inspection centre, with strong technology research and development strength. We also have 3 salesdepartments over 30 people and sell our products all over the world.
For customer`s needs, OEM service is also acceptable. If you have a good idea in new product production but lack of laboratory device and human resource, we are glad to solve this problem for you. Sincerely hope to strengthen exchanges and cooperation with friends from both home and abroad.
Two Chinese independent research and development of PD-1 antibody drugs have been listed
Medical Network January 7th Recently, two Chinese independent research and development of PD-1 antibody drugs have been listed. Cindalimumab injection was conditionally approved for listing on December 24, 2018. Prior to this, the first domestic PD-1 antibody drug, Treiprilizumab injection, was approved for marketing on December 17, 2018.
According to the news released by the website of the State Drug Administration, Xindeli monoclonal antibody injection is a kind of innovative medicine independently researched and developed by Chinese enterprises and possesses completely independent intellectual property rights. It has been supported by the national major new drug creation and key research and development plan projects. The review and approval process was approved for the treatment of relapsed or refractory classic Hodgkin's lymphoma undergoing second-line chemotherapy.
Hodgkin's lymphoma is a rare B-cell malignant lymphoma that occurs mostly in young people between the ages of 20 and 40. Although its early treatment effect is better and the cure rate is higher, there is still about 20% recurrence rate after first-line treatment. Relapsed or refractory classic Hodgkin's lymphoma currently lacks effective treatment methods and means.
It is understood that, unlike traditional chemotherapy and targeted therapy, PD-1 antibody drugs can kill tumors by overcoming the immune suppression of patients and re-activating their own immune cells. Clinical data show that sindolib monoclonal injection can bring significant clinical benefit to patients with relapsed or refractory classic Hodgkin's lymphoma, and the safety risk is controllable.
It is reported that domestic companies are enthusiastic about the research and development of innovative biological products. More than 200 anti-tumor drugs or biosimilar drugs have been approved for clinical use. On December 17, 2018, the State Drug Administration conditionally approved the first domestic PD-1 antibody drug, Treiprilizumab injection, for the treatment of local progression or metastatic melanin after failure of previous standard treatment. tumor. (Reporter Lin Miaomiao Qiu Bingqing)